Director: James B. Bussel, MD
The three major aims for fellows in the Thrombocytopenia Program are as follows:
This includes consideration of features of thrombocytopenia that would suggest “so-called” nonimmune thrombocytopenia. The first part of the first aim is to distinguish systemic illnesses that might include thrombocytopenia.
The second part of this first aim is to recognize features leading to the diagnosis of nonimmune thrombocytopenia.
In general, for management of NIT the options are limited to DDAVP, Amicar, platelet transfusion, and more recently, recombinant VIIa. The keys are recognizing which patients are sufficiently affected not to use DDAVP and when the risk of life-or-organ-threatening bleeding is high enough to justify platelet transfusion. Patients with antiplatelet antibodies or those with serious but not life-threatening bleeding may try FVIIa; insufficient data is available to diagnose who will respond and who may develop thrombosis with it. The biggest issue is usually to decide on whether any treatment is required. Finally, location-specific treatment may be used, such as Amicar for dental work or nosebleeds, birth control pills or Provera or estrogen for vaginal bleeding, or vaporizers, packing and, if necessary, cautery for epistaxis.
This is a considerably debated area and therefore, there is no clear right answer in most cases. For this reason, recognizing the appropriate choice of treatment is important. This includes being able to understand the rate of platelet increase associated with the different therapies, as well as the other advantages and disadvantages of each therapy with regard to duration of effect and to toxicities. This is a complex ever-changing field with many alternatives because no one alternative is a clearly superior alternative. The fellow needs to learn about all of the potential choices and what the pros and cons of each one are.
The fellow learns these skills primarily on the outpatient rotation at NewYork-Presbyterian Hospital-Weill Medical College of Cornell University. The fellow will see a number of patients on the ITP Service during the rotation, including patients who have nonimmune thrombocytopenia. By seeing a number of these patients, presenting their diagnosis, treatment and care, and discussing their disease progression, the fellow will learn from experience to handle the three objectives described above. The third one is the most complicated in certain ways, and the fellow benefits from the number of complex cases sent to the ITP Service for second opinions.
The goals for this experience are expertise in:
The goals will be achieved by an intensive clinical experience in hemophilic comprehensive and acute care.
The Regional Comprehensive Hemophilia Diagnostic and Treatment Center currently cares for patients with hemophilia and other coagulopathies.
The clinical program is currently expanding its patient care services. An Isotopic Synovectomy Program has been developed in collaboration with Pediatric Rheumatology and Orthopedics at the Hospital for Special Surgery. It is the first of its kind in the New York State area, and it is anticipated that it will become a regional referral center for outpatient radionuclide synovectomies for hemophilia and rheumatology patients.
In addition, program expansion to include NewYork Hospital-based pediatric dentistry is underway. Although this program currently cares for all NYPH-WMC’s bleeding disorder patients, the goal of the current project is to have dental residents and fellows rotate through the hemophilia clinic to further their education on the implications of bleeding diatheses on dental care.
Finally, the clinical program has added physiatry to its consultative services.
The goals of this experience are development of expertise in the etiology, diagnosis, and treatment of the following areas:
Pediatric patients with possible bleeding disorders will be screened through a weekly coagulation/thrombophilia clinic. This clinic evaluates all physician referrals and patient self-referrals from both within and outside the extensive Weill-Cornell Hospital network system.
A major initiative of NYPH has been the incorporation of pediatric thrombophilia care into the Hemophilia Diagnostic and Treatment Center mission. The active anticoagulation service follows pediatric (and some adult) patients on Coumadin/Low Molecular Weight Heparin long-term therapy. Teaching, home/clinic lab monitoring, and supportive care for these patients are coordinated by Hemophilia Diagnostic and Treatment Center nurses.
The Pediatric Hematology/Oncology Service handles approximately 300 consults per year (25 to 30 each month) in a.) pediatric inpatients; b.) ER patients; c.) oncology and SCT patients at NYPH and MSKCC. The majority (80 percent) of these consults are for disorders in hemostasis and thrombosis.
The goals for this rotation are the following:
The Clinical Coagulation Laboratory at NYPH performs the complete range of coagulation assays using state-of-the-art robotics. Molecular diagnostics capacity is currently being developed.
Director: Patricia J. Giardina, MD
The fellowship training program in the thalassemia syndromes is incorporated into two months of outpatient rotation and two months of inpatient rotation, which take place during the first year of clinical training. During these rotations, the goals and objectives of the fellows’ training include expertise in the following specific topic areas:
During the inpatient rotations, the fellows take active care of patients with acute complications of thalassemia disorders, as well as those patients admitted to the Clinical Research Center on protocol studies. The inpatient team consists of one attending physician, three to four rotating residents, and the fellow. During these rotations, the fellows learn the basic principles of diagnosis and treatment of various complications of thalassemia.
The fellows’ involvement with each patient includes:
Each item is then reviewed with the attending physician on a daily basis.
A manual of guidelines for diagnosis and treatment of thalassemia is included in the annual fellowship manual.
Fellows routinely attend the Outpatient Thalassemia Clinic, which is held three days each week, as well as on Tuesday evenings and alternate Thursday evenings.
In clinic fellows have the opportunity to evaluate new patients with thalassemia, as well as other non-thalassemia hemoglobinopathies requiring transfusion therapies. All new patients are seen by the fellows for diagnostic evaluation. Previously diagnosed patients are seen for quarterly comprehensive medical and psychosocial visits on Thursdays.
The fellows write the transfusion and medication orders for each clinic and are responsible for coordinating and evaluating all the new thalassemia patients. In addition, fellows are responsible for coordinating quarterly visits for returning patients in the Thursday AM and alternate Thursday PM clinics. The fellows work along with the psychologist, social worker, genetic counselor, and nurse practitioner as necessary. Fellows review patient’s treatment plans with the attending physician. Patient evaluations include history, physical examination, review of medications, interpretation of laboratory results, writing prescriptions, and determining return visits. Upon review with the attending physician, treatment plans are developed and modified as necessary.
The fellowship training program in sickling disorders is incorporated into two months of outpatient rotation and two months of inpatient rotation, which take place during the first year of training. During these rotations, the goals and objectives of the fellows’ training include mastery of the following specific topics:
During the inpatient rotations, the fellows take active care of patients with sickling disorders. The inpatient team consists of one attending physician, three to four rotating residents, and the fellow. During these rotations, the fellows learn the basic principles of diagnosis and treatment of various complications of sickle cell disease. Their involvement with each patient includes:
Each item is then reviewed with the attending physician on a daily basis.
A manual of guidelines for diagnosis and treatment of sickling disorders is included in the annual fellowship manual.
Fellows routinely attend Sickle Cell Clinic, which is held twice monthly. In clinic they have the opportunity to evaluate new patients with sickling disorders, as well as other non-sickling hemoglobinopathies. Previously diagnosed patients are also seen for follow-up and evaluated by fellows. Evaluation includes history, physical examination, review of medications, and interpretation of laboratory results. Upon review with the attending physician, treatment plans are developed and modified as necessary.